PCSK9抑制剂在糖尿病患者调脂治疗中的应用

Application of PCSK9 inhibitors in lipid-regulating therapy in patients with diabetes mellitus

前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂能够使低密度脂蛋白受体(LDL-R)的降解减少,增加LDL-R在肝细胞表面与低密度脂蛋白-胆固醇(LDL-C)结合的机会,使得LDL-C进入肝脏被清除,降低LDL-C水平及心血管事件的发生率.循环中的PCSK9抑制剂不影响血糖的调控,能够使糖尿病患者糖化血红蛋白及空腹血糖保持稳定,不增加血糖正常者的糖尿病患病率,是目前降脂药物的新靶点.

Preprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor can reduce the degradation of low density lipoprotein receptor (LDL-R),increase the opportunity for LDL-R to bind to low density lipoprotein-cholesterol (LDL-C) on the surface of hepatocytes,make LDL-C enter the liver and be cleared,thereby reducing the level of LDL-C and the incidence of cardiovascular events.PCSK9 inhibitors in circulation do not affect the regulation of blood glucose,which can keep glycosylated hemoglobin and fasting blood glucose stable in diabetic patients,and do not increase the prevalence of diabetes in people with normal blood glucose.So PCSK9 inhibitors are the new targets of lipid-lowering drugs at present.